Evaluating Alternative Designs of a Multilevel HIV Intervention in Maharashtra, India: The Impact of Stakeholder Constraints

Anik R Patel, Kelly V Ruggles, Kimberly Nucifora, Qinlian Zhou, Stephen Schensul, Jean Schensul, Kendall Bryant, R Scott Braithwaite, Anik R Patel, Kelly V Ruggles, Kimberly Nucifora, Qinlian Zhou, Stephen Schensul, Jean Schensul, Kendall Bryant, R Scott Braithwaite

Abstract

Background. Multilevel interventions combine individual component interventions, and their design can be informed by decision analysis. Our objective was to identify the optimal combination of interventions for alcohol-using HIV+ individuals on antiretroviral drug therapy in Maharashtra, India, explicitly considering stakeholder constraints. Methods. Using an HIV simulation, we evaluated the expected net monetary benefit (ENMB), the probability of lying on the efficiency frontier (PEF), and annual program costs of 5,836 unique combinations of 15 single-focused HIV risk-reduction interventions. We evaluated scenarios of 1) no constraints (i.e., maximize expected value), 2) short-term budget constraints (limits on annual programmatic costs of US$200,000 and $400,000), and 3) a constraint stemming from risk aversion (requiring that the strategy has >50% PEF). Results. With no constraints, the combination including long individual alcohol counseling, text-message adherence support, long group counseling for sex-risk, and long individual counseling for sex-risk (annual cost = $428,886; PEF ∼27%) maximized ENMB and would be the optimal design. With a cost constraint of $400,000, the combination including long individual alcohol counseling, text-message adherence support, brief group counseling for sex-risk, and long individual counseling for sex-risk (annual cost = $374,745; PEF ∼4%) maximized ENMB. With a cost constraint of $200,000, the combination including long individual alcohol counseling, text-message adherence support, and brief group counseling for sex-risk (annual cost = $187,335; PEF ∼54%) maximized ENMB. With the risk aversion constraint, the same configuration (long individual alcohol counseling, text-message support, and brief group counseling for sex-risk) maximized health benefit. Conclusion. Evaluating the costs, risks, and projected benefits of alternatives supports informed decision making prior to initiating study; however, stakeholder constraints should be explicitly included and discussed when using decision analyses to guide study design.

Keywords: HIV; constrained optimization; decision analytic modeling; economic evaluation; study design.

Conflict of interest statement

The following author is employed by the sponsor: Kendall Bryant. The other authors have not conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Simulation structure and dynamics. In order to simulate interventions that had individual patient benefits and population benefits, this analysis involved an individual-level microsimulation combined with a compartmental dynamic transmission model. Further details of the simulation calculations and logic can be found in the technical appendix.
Figure 2
Figure 2
Optimal options considering programmatic budget constraints. (A) The optimal options with a 1-year program cost below $200,000. If a funder perceived uncertainty in future health care budgets, they may impose a restriction on what to study based on annual program costs. (B) The optimal options with 1-year program cost below $400,000. A constraint on annual spending is a manifestation of an implicitly high discount rate. It may be driven in part by uncertainty in future sources of financing. (C) Under no cost constraint, all five options are considered. These five configurations were the most efficient, but each had different programmatic costs and probability of being most efficient. Decision analysis eliminated 5,815 of the 5,836 options, leaving 22 choices to consider.
Figure 3
Figure 3
Optimal options considering a risk-averse decision maker. (A) The optimal options with a constraint of having at least a 50% chance of being on the efficiency frontier would leave two of the five options. (B) Decision makers may have alternative levels of risk requirements, so presenting the risk along with the expected value can make the tradeoff between more extensive intervention packages and risk of inefficiency relative to less intense intervention packages more explicit.

References

    1. World Health Organization. Treat all people living with HIV, offer antiretrovirals as additional prevention choice for people at “substantial” risk [cited June10, 2016]. Available from:
    1. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach. 2nd ed.Geneva: World Health Organization; 2016.
    1. International Institute for Population Sciences. National Family Health Survey, India 2005-06 NFHS-3 [cited July 11, 2016]. Available from:
    1. Cleary PD, Gross CP, Zaslavsky AM, Taplin SH. Multilevel interventions: study design and analysis issues. J Natl Cancer Inst Monogr. 2012;2012(44):49–55.
    1. Schensul JJ, Trickett E. Introduction to multi-level community based culturally situated interventions. Am J Community Psychol. 2009;43(3–4):232–40.
    1. Stewart R, Niessen WJ, Broer J, Snijders TA, Haaijer-Ruskamp FM, Meyboom-De Jong B. General practitioners reduced benzodiazepine prescriptions in an intervention study: a multilevel application. J Clin Epidemiol. 2007;60(10):1076–84.
    1. Foxcroft DR, Coombes L, Wood S, Allen D, Santimano NMA. Motivational interviewing for alcohol misuse in young adults. Cochrane Database Syst Rev. 2014;(8):CD007025.
    1. Scott-Sheldon LA, Huedo-Medina TB, Warren MR, Johnson BT, Carey MP. Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis, 1991 to 2010. J Acquir Immune Defic Syndr. 2011;58(5):489–98.
    1. Moreno R, Nababan HY, Ota E, et al. Structural and community-level interventions for increasing condom use to prevent the transmission of HIV and other sexually transmitted infections. Cochrane Database Syst Rev. 2014;(7):CD003363.
    1. Spies G, Asmal L, Seedat S. Cognitive-behavioural interventions for mood and anxiety disorders in HIV: a systematic review. J Affect Disord. 2013;150(2):171–80.
    1. Mills EJ, Lester R, Thorlund K, et al. Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysis. Lancet HIV. 2014;1(3):e104–e111.
    1. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015,93(2):118–24.
    1. Hunink MM, Weinstein MC, Wittenberg E, et al. Decision Making in Health and Medicine: Integrating Evidence and Values. 2nd ed.Cambridge: Cambridge University Press; 2014.
    1. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
    1. Kahneman D, Tversky A. Prospect theory: an analysis of decision under risk. Econometrica. 1979;47(2):263–92.
    1. Kessler J, Ruggles K, Patel A, et al. Targeting an alcohol intervention cost-effectively to persons living with HIV/AIDS in East Africa. Alcohol Clin Exp Res. 2015;39(11):2179–88.
    1. Braithwaite RS, Nucifora KA, Yiannoutsos CT, et al. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? J Int AIDS Soc. 2011;14(1):38.
    1. Srasuebkul P, Calmy A, Zhou J, Kumarasamy N, Law M, Lim PL; TREAT Asia HIV Observational Database. Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD). AIDS Res Ther. 2007;4:18.
    1. Jamison JC, Karlan D, Raffler P. Mixed-Method Evaluation of a Passive mHealth Sexual Information Texting Service in Uganda (Working Paper 19107). Cambridge: National Bureau of Economic Research; 2013.
    1. Johns B, Baltussen R, Hutubessy R. Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc. 2003;1(1):1.
    1. World Health Organization. Choosing effectiveness and strategic planning (WHO-CHOICE) [cited July 11, 2016]. Available from:
    1. Briggs AH, Goeree R, Blackhouse G, O’Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22(4):290–308.
    1. Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health. 2008;11(5):886–97.
    1. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18(3):341–64.
    1. World Bank. GDP per capita (current US$) [cited July 11, 2016]. Available from:
    1. Koerkamp BG, Hunink MM, Stijnen T, Hammitt JK, Kuntz KM, Weinstein MC. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making. 2007;27(2):101–11.

Source: PubMed

3
订阅